Streetbeat News

ORKA

Oruka Therapeutics, Inc.

http://www.orukatx.com

Industry

Biotechnology

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Oruka Therapeutics presented preclinical data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting, showing a half-life in non-human primates of over 30 days, which is significantly longer than bimekizumab. This suggests a dosing interval of two to three times per year.

Portfolio Pulse from

March 07, 2025 | 1:45 pm

Oruka Therapeutics, a clinical stage biotech company, will present at multiple investor conferences in March. The company focuses on developing novel biologics for chronic skin diseases like plaque psoriasis.

Portfolio Pulse from

February 19, 2025 | 12:15 pm

Oruka Therapeutics has begun dosing healthy volunteers in a Phase 1 trial for ORKA-001, a novel antibody targeting IL-23p19. The trial aims to gather pharmacokinetic and safety data by late 2025, with a proof-of-concept study in psoriasis planned for the same period. Initial efficacy data is expected by late 2026.

Portfolio Pulse from

December 19, 2024 | 12:15 pm

Oruka Therapeutics has reported its third quarter 2024 financial results, highlighting a successful go-public transaction and raising over $475 million this year. This funding provides a cash runway through multiple clinical inflection points.

Portfolio Pulse from

November 13, 2024 | 9:45 pm

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Oruka Therapeutics (NASDAQ:ORKA) and maintained a price target of $45.